Handelsbanken Fonder AB Buys New Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Handelsbanken Fonder AB bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) in the fourth quarter, HoldingsChannel reports. The firm bought 178,700 shares of the company’s stock, valued at approximately $3,937,000.

Other hedge funds also recently bought and sold shares of the company. New York State Common Retirement Fund grew its holdings in Cellebrite DI by 2.6% during the 4th quarter. New York State Common Retirement Fund now owns 189,599 shares of the company’s stock worth $4,177,000 after acquiring an additional 4,838 shares in the last quarter. Pembroke Management LTD boosted its stake in Cellebrite DI by 4.4% during the 4th quarter. Pembroke Management LTD now owns 1,992,432 shares of the company’s stock worth $43,893,000 after purchasing an additional 84,087 shares during the last quarter. Strategic Advisors LLC boosted its position in shares of Cellebrite DI by 3.4% during the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock valued at $641,000 after acquiring an additional 950 shares during the last quarter. Blue Trust Inc. purchased a new stake in Cellebrite DI in the 4th quarter valued at about $468,000. Finally, Van ECK Associates Corp purchased a new stake in Cellebrite DI during the fourth quarter worth about $639,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $19.12 on Monday. The firm’s 50 day simple moving average is $22.54 and its 200-day simple moving average is $19.47. Cellebrite DI Ltd. has a fifty-two week low of $10.24 and a fifty-two week high of $26.30. The company has a market cap of $3.94 billion, a P/E ratio of -13.76, a price-to-earnings-growth ratio of 4.27 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on CLBT shares. Craig Hallum boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a research note on Friday, February 14th. Finally, Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.